Research programme: metabolic disease therapeutics - Second Genome

Drug Profile

Research programme: metabolic disease therapeutics - Second Genome

Latest Information Update: 10 Oct 2014

Price : $50

At a glance

  • Originator Second Genome
  • Developer Mayo Clinic; Pfizer; Second Genome
  • Class Peptides; Small molecules
  • Mechanism of Action Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Research Metabolic disorders; Obesity

Most Recent Events

  • 07 Oct 2014 Early research in Metabolic disorders in USA (unspecified route)
  • 07 Oct 2014 Second Genome enters into a collaboration with Mayo Clinic Center to support development of therapeutics for multiple disease indications, including metabolic disorders
  • 02 May 2014 Early research in Obesity in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top